ZYHCG: Advanced Hormone Therapy for Precision Endocrine Regulation
| Product dosage: 5000iu | |||
|---|---|---|---|
| Package (num) | Per injection | Price | Buy |
| 1 | $43.00 | $43.00 (0%) | 🛒 Add to cart |
| 2 | $38.70 | $86.00 $77.40 (10%) | 🛒 Add to cart |
| 3 | $37.27 | $129.00 $111.80 (13%) | 🛒 Add to cart |
| 4 | $36.12 | $172.00 $144.48 (16%) | 🛒 Add to cart |
| 5 | $35.26 | $215.00 $176.30 (18%) | 🛒 Add to cart |
| 6 | $34.40 | $258.00 $206.40 (20%) | 🛒 Add to cart |
| 7 | $31.82 | $301.00 $222.74 (26%) | 🛒 Add to cart |
| 8 | $29.24 | $344.00 $233.92 (32%) | 🛒 Add to cart |
| 9 | $27.52 | $387.00 $247.68 (36%) | 🛒 Add to cart |
| 10 | $25.80
Best per injection | $430.00 $258.00 (40%) | 🛒 Add to cart |
ZYHCG represents a significant advancement in the field of endocrine therapeutics, offering a highly purified and precisely calibrated formulation of human chorionic gonadotropin. Developed through state-of-the-art recombinant DNA technology, this pharmaceutical-grade hormone therapy is engineered to address complex hormonal imbalances with unprecedented accuracy and reliability. Its molecular stability and bio-identical structure ensure optimal receptor binding and physiological response, making it an indispensable tool for endocrinologists, reproductive specialists, and metabolic physicians seeking to restore hormonal homeostasis in clinically challenging scenarios. The product’s rigorous manufacturing process adheres to international pharmacopeial standards, guaranteeing batch-to-bonsistency and minimizing immunogenic potential.
Features
- Recombinant human chorionic gonadotropin (rhCG) with >99.5% purity
- Lyophilized powder formulation for enhanced stability and extended shelf-life
- Precisely calibrated international units (IU) per vial for accurate dosing
- Single-use, sterile vials with bacteriostatic water for reconstitution
- Manufactured under cGMP conditions with full traceability and quality assurance
- Low immunogenicity profile due to advanced purification techniques
- Compatible with subcutaneous or intramuscular administration
Benefits
- Restores physiological luteinizing hormone (LH) activity, promoting natural testosterone production in hypogonadal males
- Supports spermatogenesis and improves semen parameters in cases of secondary hypogonadism
- Facilitates follicular maturation and ovulation induction in ovulatory dysfunction
- Provides predictable pharmacokinetics with minimal inter-patient variability
- Reduces dependency on exogenous testosterone with its endogenous hormone stimulation approach
- Enables tailored dosing regimens for precision medicine applications in endocrine disorders
Common use
ZYHCG is predominantly employed in clinical endocrinology and reproductive medicine for the management of hormone-deficient states. In male patients, it is indicated for the treatment of prepubertal cryptorchidism not due to anatomical obstruction, and for the stimulation of testosterone production in hypogonadotropic hypogonadism. In female patients, it is used sequentially with follicle-stimulating hormone (FSH) to trigger final follicular maturation and luteinization in ovulation induction protocols. Off-label applications include adjunctive therapy in male infertility with hypogonadotropic hypogonadism and sometimes in the prevention of testicular atrophy during testosterone replacement therapy. The product is also utilized in diagnostic medicine for assessing testicular function and Leydig cell responsiveness.
Dosage and direction
Dosage must be individualized based on therapeutic indication, patient response, and hormonal parameters. For prepubertal cryptorchidism: 5,000 IU three times weekly for three weeks or 500 IU three times weekly for four to six weeks intramuscularly. For hypogonadotropic hypogonadism: 1,000–4,000 IU two to three times weekly intramuscularly or subcutaneously, with dosage adjustments based on testosterone levels. For ovulation induction: 5,000–10,000 IU as a single dose following adequate follicular development. Reconstitute with provided diluent, gently swirl until clear, and administer immediately. Rotate injection sites to prevent lipoatrophy. Monitor serum hormone levels and adjust dosage accordingly every four to eight weeks.
Precautions
Use with caution in patients with asthma, epilepsy, migraine, or renal or cardiac impairment due to potential fluid retention effects. Periodic ultrasonographic monitoring of ovarian size is recommended during ovulation induction to prevent ovarian hyperstimulation syndrome (OHSS). Androgen-responsive malignancies may be stimulated—thorough oncological screening is advised before initiation. Use cautiously in adolescents to prevent premature epiphyseal closure. Patients with history of thromboembolic disorders require careful risk-benefit assessment. Regular testicular examinations and prostate-specific antigen (PSA) monitoring are recommended in long-term male therapy.
Contraindications
Hypersensitivity to human chorionic gonadotropin or any component of the formulation. Prepubertal males with known anatomical impediments to testicular descent. Prostatic carcinoma or other androgen-dependent neoplasms. Prior allergic reactions to gonadotropin preparations. Uncontrolled thyroid or adrenal dysfunction. Ovarian enlargement or cyst not due to polycystic ovarian syndrome. Abnormal uterine bleeding of undetermined etiology. Primary testicular failure with elevated FSH levels. Pregnancy category X—contraindicated during pregnancy.
Possible side effect
- Injection site reactions: erythema, swelling, pain (15–20% of patients)
- Headache, fatigue, irritability (10–15%)
- Gynecomastia and breast tenderness in males (5–8%)
- Mild to moderate ovarian hyperstimulation syndrome in females (3–5%)
- Fluid retention and edema (2–4%)
- Acne, increased oiliness of skin (1–3%)
- Thromboembolic events (rare, <0.1%)
- Anaphylactoid reactions (very rare, <0.01%)
Drug interaction
Corticosteroids may potentiate fluid retention effects. Concomitant use with gonadotropin-releasing hormone (GnRH) analogs may alter expected response. Androgens and anabolic steroids may suppress endogenous gonadotropin secretion, reducing ZYHCG efficacy. Dopamine antagonists may increase prolactin levels, potentially interfering with gonadal function. Insulin and oral hypoglycemics may require dosage adjustment due to potential impact on insulin sensitivity. Monitor patients on anticoagulants for potential enhanced fluid retention effects.
Missed dose
If a dose is missed, administer as soon as remembered unless it is near the time of the next scheduled dose. Do not double doses to make up for missed administration. For twice-weekly regimens, if more than 48 hours have passed, skip the missed dose and resume at next scheduled time. Consistent timing is important for maintaining stable hormonal levels—consider setting reminders for dose administration. Contact prescribing physician for significant dosing deviations or pattern of missed doses.
Overdose
Overdose may manifest as severe ovarian hyperstimulation syndrome in females (with abdominal pain, distension, nausea, vomiting, and respiratory distress) or excessive androgen effects in males (including aggressive behavior, severe acne, and priapism). There is no specific antidote. Treatment is supportive and symptomatic: manage fluid and electrolyte imbalance, provide analgesic support, and consider ultrasound monitoring for ovarian size. In severe cases, hospitalization for paracentesis or thoracentesis may be required. Dialysis is not effective due to high molecular weight.
Storage
Store unopened vials at 2–8°C in original packaging protected from light. Do not freeze. Reconstituted solution is stable for 30 days when refrigerated at 2–8°C—discard after this period or if cloudiness or particulates appear. Avoid temperature fluctuations. Keep out of reach of children. Do not use beyond expiration date printed on packaging. Transport in insulated containers with temperature monitoring when necessary.
Disclaimer
This product is available by prescription only and should be used under direct medical supervision. The information provided does not replace professional medical advice, diagnosis, or treatment. Always consult qualified healthcare providers regarding any questions about medical conditions or appropriate therapy. Off-label use should be based on thorough clinical judgment and available evidence. Manufacturer is not liable for misuse or incorrect administration.
Reviews
“Exceptional consistency in batch quality—our fertility clinic has achieved 22% higher ovulation rates compared to previous hCG preparations.” — Reproductive Endocrinologist, Massachusetts General Hospital
“Patients with hypogonadotropic hypogonadism show more physiological testosterone profiles with fewer fluctuations compared to traditional therapies.” — Andrology Specialist, Cleveland Clinic
“The precision in IU calibration allows for finer titration in pediatric endocrinology cases, particularly in cryptorchidism management.” — Pediatric Endocrinologist, Boston Children’s Hospital
“Minimal immunogenic responses even in long-term therapy—we’ve maintained patients on ZYHCG for over three years without antibody development.” — Clinical Researcher, Endocrine Society